GLP-1RAs have pleiotropic effects: they improve neurogenesis, reduce apoptosis, protect neurons from oxidative stress, and reduce neuroinflammation in various neurological conditions, and it is these beneficial effects that can be used in aging-related diseases, mainly AD and PD
Missing doses, incorrect injection sites, or improper storage of medication can all reduce effectiveness
Thus, a systematic review of the efficacy of GLP-1RAs in terms of their effect on the underlying pathology of AD and improvement of cognitive functions, which included 6 articles that met the criteria (4 randomized control studies and 2 protocol studies) [53], indicates that GLP-1RA therapy in AD did not alter -amyloid and tau protein biomarkers and did not improve cognitive abilities, but demonstrated potential metabolic and neuroprotective benefits
The drug reduced depression-like behaviors in these mice and also improved learning and memory when they were not under stress
They are not inevitable or irreversible, but they do warrant attention rather than being treated as an acceptable side effect to push through
